Recombinant DNA techniques: A systematic review

Sunita Sharma Sunita Sharma

Sunita Sharma NRI Vidyadayani Institute of Science, Management and Technology, Bhopal-462044, MP (India)

Abstract

Recombinant DNA-innovation is one further stride of hereditary building, which empowers us to large scale manufacturing of sheltered, immaculate and compelling natural items. Recombinant DNA is falsely made from at least two DNA consolidated into a solitary atom. Hereditary designing, recombinant DNA innovation, hereditary adjustment/control and quality grafting are terms that are connected to the immediate control of a living being's quality. Recombinant DNA is utilized to deliver biochemicals, for example, hormones of restorative intrigue, haemopoietic development variables, blood coagulation items, thrombolytic operators, anticoagulants, interferon, interleukins and helpful chemicals. Utilizing RDT, researchers are attempting to create environment-accommodating other options to fossil fills and plastics; new medications, immunizations and illness indicative instruments and higher yielding and more supplement rich harvest plants. RDT influences all aspects of our lives in the 21st century. This audit is underscoring the significance of recombinant DNA innovation and their applications utilized for human welfare.

Keywords: Recombinant DNA technology, Vaccines, Gene cloning, Genetic engineering, Thrombolytic agents

Downloads

Download data is not yet available.

References

1.Alfermann AW, Peterson M. Natural product formation by plant cell biotechnology, results and perspectives. Plant Cell, Tissue Organ Cult 1995; 43: 199-205.
2. An X, Lu J, Huang J, Zhang B, Liu D, et al. Rapid assembly of multiple‐exon cDNA directly from genomic DNA. PLoS One 2007; 2: 1179.
3. Bailey JE. Toward a science of metabolic engineering. Science 1991; 252: 1668-1675.
4. Bajaj YPS, Ishimaru K. Genetic transformation of medicinal plants. In: Transgenic Medicinal Plants. Biotechnology in Agriculture and Forestry 45, Springer, New Delhi (Ed. Bajaj YPS), 1999: 1-29.
5. Bond SR, Naus CC. RF-Cloning.org: an online tool for the design of restriction-free cloning projects. Nucleic Acids Res 2012; 40: 209-213.
Cheo DL, Titus SA, Byrd DR, Hartley JL, Temple GF, Brasch MA. Concerted assembly and cloning of multiple DNA segments using in vitro site-specific recombination: functional analysis of multi-segment expression clones. Genome Res 2004; 14: 2111-2120.
7. Court DL, Sawitzke JA, Thomason LC. Genetic engineering using homologous recombination. Annu Rev Genet 2002; 36: 361-388.
8. Fujita Y. Industrial production of shikonin and berberine. In: Application of Plant Cell and Tissue Culture. John Wiley & Sons, Chichester, UK: CIBA Foundation Symposium 137. (eds. Bock G, Marsh J), 1998: 228-235.
9. Marchuk D, Drumm M, Saulino A, Collins F. Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products. Nucleic Acids Res 1991; 19: 1154.
10. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. CSH Laboratory Press: Cold Spring Harbor, New York 2001.
11. Sharp JM, Doran PM. Characteristics of growth and tropane alkaloid synthesis in Atropa belladonna roots transformed by Agrobacterium rhizogenes. J Biotechnol 1990; 16: 171-186.
12. Shuldiner AR, Scott LA, Roth J. PCR induced (ligase-free) subcloning: A rapid reliable method to subclone polymerase chain reaction (PCR) products. Nucleic Acids Res 1990; 18: 1920
13. Mc Evoy GK. AHFS drug information, American Society of Health System Pharmacists, Bethesda, 2001: 2977-2998.
14. Chapman, TM, Noble S, Goa KL. Insulin aspart: A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs, 2002, 62: 1945-1981.
15. Dunn CJ, Plosker GL, Keating GM, Mckeage K, Scott LJ. Insulin glargine: An updated review of its use in the management of diabetes mellitus. Drugs 2003; 63: 1743-1478.
16. Dunn J, Plosker GL. Insulin lispro: A pharmaco economic review of its use in diabetes mellitus. Pharmacoeconomics 2002; 20: 989-1025.
17. Vazquez-Carrera, Silvestre JS. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol 2004; 26: 445–461.
18. Hugues JN. Recombinant human follicle-stimulating hormone: A scientific step to clinical improvement. Reprod Biomed Online 2001; 2: 54-64.
19. Cheon KM, Byun HK, Yang KM, Song IO, Choi KH, Yoo KJ. Efficacy of recombinant human follicle stimulating hormone in improving oocyte quality in assisted reproductive techniques. J Report Med 2004; 49: 733-738.
20. Mehta A, Hindmarsh PC. The use of somatropin (recombinant growth hormone) in children of short stature paediatr. Drugs 2002; 4: 37-47.
21. Markham A, Bryson HM. Epoetin alfa, a review of its pharmacodynamics and pharmacokinetic properties and therapeutic use in non renal application. Drugs 1995; 49: 232-254.
22. Joy MS. Darbepoetin alfa: A novel erythropoiesis stimulating protein. Ann Pharmacother 2002; 36:1183-1192.
23. Bhopale GM, Nanda RK. Blood coagulation factor VIII: An overview. J Biosci 2003; 23: 783-789.
24. Berntrop PE, et al. Modern treatment of hemophilia. Bull. W.H.O. 1995; 73: 691-701.
25. Doggrell SA. Alteplase: Descendancy in myocardial infarction, ascendancy in stroke. Expert Opin Investing Drugs 2001: 2013-2029.
26. Greinacher A. Lepirudin: A bivalent direct thrombin inhibitor for anticoagulation therapy. Expert Rev Cardiovasc Ther 2004; 2: 339-357
27. Barrows LR. Antineoplastic and immunoactive drugs. In The Science and Practice and Pharmacy (ed. Gennaro, A. R.), Remington, 2000: 1495.